Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression

European Neuropsychopharmacology

Volumn 26, Issue 9, 2016, Pages 1475-1483

  Pettai, Kristi ^a   Milani, Lili ^a   Tammiste, Anu ^a   Võsa, Urmo ^a   Kolde, Raivo ^b,c   Eller, Triin ^b   Nutt, David ^d   Metspalu, Andres ^a,b   Maron, Eduard ^b,d,e  

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c North Estonia Medical Centre ^*  (Estonia)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e North Estonia Medical Centre   (Estonia)

Author keywords

Escitalopram; Gene expression; Major depression; SSRI; Treatment prediction

Indexed keywords

BIOLOGICAL MARKER; ESCITALOPRAM; MEMBRANE PROTEIN; NEUROTROPHIN; NUCLEAR RECEPTOR NR2C2; ANTIDEPRESSANT AGENT; CITALOPRAM; FK 506 BINDING PROTEIN; FKBP1A PROTEIN, HUMAN; NR2C2 PROTEIN, HUMAN; STEROID RECEPTOR; THYROID HORMONE RECEPTOR; TRANSACTIVATOR PROTEIN; ZNF641 PROTEIN, HUMAN;

ADULT; ARTICLE; FEMALE; FKBP1A GENE; GENE; GENE CLUSTER; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MICROARRAY ANALYSIS; MICROARRAY KIT; NERVE CELL; NLGN2 GENE; OUTPATIENT; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; SYNAPSE; TREATMENT OUTCOME; TREATMENT RESPONSE; YWHAZ GENE; ZNF641 GENE; GENE EXPRESSION PROFILING; GENETICS; GENOME; PSYCHOLOGICAL RATING SCALE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE EXPRESSION PROFILING; GENOME; HUMANS; MALE; MICROARRAY ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, STEROID; RECEPTORS, THYROID HORMONE; TACROLIMUS BINDING PROTEINS; TRANS-ACTIVATORS; TREATMENT OUTCOME;

EID: 84979059285     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2016.06.007     Document Type: Article

References (47)

1. Baik, S.Y., Jung, K.H., Choi, M.R., Yang, B.H., Kim, S.H., Lee, J.S., et al. Fluoxetine-induced up-regulation of 14-3-3zeta and tryptophan hydroxylase levels in RBL-2H3 cells. Neurosci. Lett. 374 (2005), 53–57.
2. Belzeaux, R., Bergon, A., Jeanjean, V., Loriod, B., Formisano-Treziny, C., Verrier, L., et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl. Psychiatry, 2, 2012, e185.
3. Bennabi, D., Aouizerate, B., El-Hage, W., Doumy, O., Moliere, F., Courtet, P., et al. Risk factors for treatment resistance in unipolar depression: a systematic review. J. Affect. Disord. 171 (2015), 137–141.
4. Bruce, T.O., Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr. Psychiatry Rep. 10:3 (2008), 258–264.
5. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67:5 (2010), 446–457.
6. Eller, T., Vasar, V., Shlik, J., Maron, E., The role of IL-2 and soluble IL-2R in depression and antidepressant response. Curr. Opin. Investig. Drugs 10:7 (2009), 638–643.
7. Galeotti, N., Vivoli, E., Bartolini, A., Ghelardini, C., A gene-specific cerebral types 1, 2, and 3 RyR protein knockdown induces an antidepressant-like effect in mice. J. Neurochem. 106:6 (2008), 2385–2394.
8. Gonul, A.S., Akdeniz, F., Taneli, F., Donat, O., Eker, C., Vahip, S., Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur. Arch. Psychiatry Clin. Neurosci. 255:6 (2005), 381–386.
9. Guilloux, J.P., Bassi, S., Ding, Y., Walsh, C., Turecki, G., Tseng, G., et al. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 40:3 (2015), 701–710.
10. Hasler, G., van der Veen, J.W., Tumonis, T., Meyers, N., Shen, J., Drevets, W.C., Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 64:2 (2007), 193–200.
11. Hepgul, N., Cattaneo, A., Zunszain, P.A., Pariante, C.M., Depression pathogenesis and treatment: what can we learn from blood mRNA expression?. BMC Med., 11, 2013, 28.
12. Huang, da W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4:1 (2009), 44–57.
13. Kalueff, A.V., Nutt, D.J., Role of GABA in anxiety and depression. Depress Anxiety 24:7 (2007), 495–517.
14. Kang, C.B., Hong, Y., Dhe-Paganon, S., Yoon, H.S., FKBP family proteins: immunophilins with versatile biological functions. Neurosignals 16:4 (2008), 318–325.
15. Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., Aubry, J.M., Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 109:2 (2002), 143–148.
16. Kennedy, S.H., Andersen, H.F., Lam, R.W., Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J. Psychiatry Neurosci.: JPN 31:2 (2006), 122–131.
17. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:23 (2003), 3095–3105.
18. Kosel, M., Rudolph, U., Wielepp, P., Luginbuhl, M., Schmitt, W., Fisch, H.U., et al. Diminished GABA(A) receptor-binding capacity and a DNA base substitution in a patient with treatment-resistant depression and anxiety. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 29:2 (2004), 347–350.
19. Labermaier, C., Masana, M., Muller, M.B., Biomarkers predicting antidepressant treatment response: how can we advance the field?. Dis. Markers 35:1 (2013), 23–31.
20. Lewis, C.M., Ng, M.Y., Butler, A.W., Cohen-Woods, S., Uher, R., Pirlo, K., et al. Genome-wide association study of major recurrent depression in the U.K. population. Am. J. Psychiatry 167:8 (2010), 949–957.
21. Lin, E., Tsai, S.J., Genome-wide microarray analysis of gene expression profiling in major depression and antidepressant therapy. Progress. Neuro-Psychopharmacol. Biol. psychiatry, 2015.
22. Malhotra, A.K., Lencz, T., Correll, C.U., Kane, J.M., Genomics and the future of pharmacotherapy in psychiatry. Int. Rev. Psychiatry 19:5 (2007), 523–530.
23. Mamdani, F., Berlim, M.T., Beaulieu, M.M., Labbe, A., Merette, C., Turecki, G., Gene expression biomarkers of response to citalopram treatment in major depressive disorder. Transl. Psychiatry, 1, 2011, e13.
24. Maron, E., Kallassalu, K., Tammiste, A., Kolde, R., Vilo, J., Toru, I., et al. Peripheral gene expression profiling of CCK-4-induced panic in healthy subjects. Am. J. Med. Genet. Part B, Neuropsychiatr. Genet.: Off. Publ. Int. Soc. Psychiatr. Genet. 153B:1 (2010), 269–274.
25. Maron, E., Tammiste, A., Kallassalu, K., Eller, T., Vasar, V., Nutt, D.J., Metspalu, A., Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur. Neuropsychopharmacol. 19:6 (2009), 451–456.
26. Mathers, C.D., Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med., 3(11), 2006, e442.
27. Matrisciano, F., Bonaccorso, S., Ricciardi, A., Scaccianoce, S., Panaccione, I., Wang, L., et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr. Res 43:3 (2009), 247–254.
28. Min, J.L., Barrett, A., Watts, T., Pettersson, F.H., Lockstone, H.E., Lindgren, C.M., et al. Variability of gene expression profiles in human blood and lymphoblastoid cell lines. BMC Genom., 11, 2010, 96.
29. Molteni, R., Calabrese, F., Bedogni, F., Tongiorgi, E., Fumagalli, F., Racagni, G., et al. Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions. Int. J. Neuropsychopharmacol. 9:3 (2006), 307–317.
30. Mrazek, D.A., Biernacka, J.M., McAlpine, D.E., Benitez, J., Karpyak, V.M., Williams, M.D., et al. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. J. Clin. Psychopharmacol. 34:3 (2014), 313–317.
31. Muller, N., Schwarz, M.J., The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 12:11 (2007), 988–1000.
32. Poulopoulos, A., Aramuni, G., Meyer, G., Soykan, T., Hoon, M., Papadopoulos, T., et al. Neuroligin 2 drives postsynaptic assembly at perisomatic inhibitory synapses through gephyrin and collybistin. Neuron 63:5 (2009), 628–642.
33. Sanacora, G., Mason, G.F., Rothman, D.L., Krystal, J.H., Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am. J. Psychiatry 159:4 (2002), 663–665.
34. Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol., 7, 2006, 3.
35. Sen, S., Duman, R., Sanacora, G., Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 64:6 (2008), 527–532.
36. Serretti, A., Kato, M., The serotonin transporter gene and effectiveness of SSRIs. Expert Rev. Neurother. 8:1 (2008), 111–120.
37. Sullivan, P.F., Fan, C., Perou, C.M., Evaluating the comparability of gene expression in blood and brain. Am. J. Med. Genet. Part B, Neuropsychiatr. Genet.: Off. Publ. Int. Soc. Psychiatr. Genet. 141B:3 (2006), 261–268.
38. Trivedi, M.H., Fava, M., Wisniewski, S.R., Thase, M.E., Quitkin, F., Warden, D., et al. Medication augmentation after the failure of SSRIs for depression. New Engl. J. Med. 354:12 (2006), 1243–1252.
39. Van de Velde, S., Bracke, P., Levecque, K., Gender differences in depression in 23 European countries. Cross-national variation in the gender gap in depression. Soc. Sci. Med 71:2 (2010), 305–313.
40. Vanderkooy, J.D., Kennedy, S.H., Bagby, R.M., Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can. J. Psychiatry Rev. Can. Psychiatr. 47:2 (2002), 174–180.
41. Varoqueaux, F., Aramuni, G., Rawson, R.L., Mohrmann, R., Missler, M., Gottmann, K., et al. Neuroligins determine synapse maturation and function. Neuron 51:6 (2006), 741–754.
42. Varoqueaux, F., Jamain, S., Brose, N., Neuroligin 2 is exclusively localized to inhibitory synapses. Eur. J. Cell Biol. 83:9 (2004), 449–456.
43. Wettenhall, J.M., Smyth, G.K., limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 20:18 (2004), 3705–3706.
44. Whitney, A.R., Diehn, M., Popper, S.J., Alizadeh, A.A., Boldrick, J.C., Relman, D.A., et al. Individuality and variation in gene expression patterns in human blood. Proc. Natl. Acad. Sci. USA 100 (2003), 1896–1901.
45. Winge, I., McKinney, J.A., Ying, M., D׳Santos, C.S., Kleppe, R., Knappskog, P.M., et al. Activation and stabilization of human tryptophan hydroxylase 2 by phosphorylation and 14-3-3 binding. Biochem. J. 410:1 (2008), 195–204.
46. Wuwongse, S., Chang, R.C., Law, A.C., The putative neurodegenerative links between depression and Alzheimer׳s disease. Prog. Neurobiol. 91:4 (2010), 362–375.
47. Zalk, R., Lehnart, S.E., Marks, A.R., Modulation of the ryanodine receptor and intracellular calcium. Annu. Rev. Biochem. 76 (2007), 367–385.